Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Nat Prod ; 84(9): 2447-2453, 2021 09 24.
Artigo em Inglês | MEDLINE | ID: mdl-34460260

RESUMO

In Alzheimer's disease (AD) the accumulation of amyloid ß (Aß) plaques in the brain leads to neuroinflammation, neuronal cell dysfunction, and progressive memory loss. Therefore, blocking the formation of Aß plaques has emerged as one of the most promising strategies to develop AD treatments. Hempseed is widely used as a food, and recently its compounds have shown beneficial effects on neuroinflammation. The objective of this study was to investigate whether a fraction rich in phenyl amide compounds, N-trans-caffeoyltyramine (CAFT) and N-trans-coumaroyltyramine (CUMT), can affect gene expression: ß-site amyloid-precursor-protein-cleaving enzyme 1 (BACE 1), peroxisome proliferator-activated receptor gamma (PPAR γ), and PPARγ-coactivator-1α (PGC-1α) in N2a-APP cells. The mRNA levels were measured using RT-qPCR. The ethyl acetate fraction and CAFT were found to reduce BACE1 gene expression and are promissory PPARγ and PGC-1α natural agonists. The results show that hempseed compounds can inhibit the expression of BACE 1, which is involved in the accumulation of Aß plaques and positively affect transcription factors involved in complex and diverse biological functions.


Assuntos
Amidas/farmacologia , Secretases da Proteína Precursora do Amiloide , Ácido Aspártico Endopeptidases , Cannabis/química , PPAR gama , Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo , Doença de Alzheimer , Peptídeos beta-Amiloides , Animais , Linhagem Celular , Expressão Gênica/efeitos dos fármacos , Camundongos , Estrutura Molecular , Compostos Fitoquímicos/farmacologia , Sementes/química , Espanha , Tiramina/farmacologia
2.
Int J Mol Sci ; 14(11): 21227-39, 2013 Oct 24.
Artigo em Inglês | MEDLINE | ID: mdl-24284391

RESUMO

We have previously shown that the Andalusian-cultivated Asparagus officinalis L. "triguero" variety produces hypocholesterolemic and hepatoprotective effects on rats. This asparagus is a rich source of phytochemicals although we hypothesized there would be some of them more involved in these functional properties. Thus, we aimed to study the effects of asparagus (500 mg/kg body weight (bw)/day) and their partially purified fractions in flavonoids (50 mg/kg bw/day), saponins (5 mg/kg bw/day) and dietary fiber (500 mg/kg bw/day) on oxidative status and on lipid profile in rats fed a cholesterol-rich diet. After 5 weeks treatment, plasma lipid values, hepatic enzyme activities and liver malondialdehyde (MDA) concentrations were measured. With the exception of the saponin fraction (SF), the administration of lyophilized asparagus (LA), fiber fraction (FF), and flavonoid fraction (FVF) to hypercholesterolemic rats produced a significant hypolipidemic effect compare to a high-cholesterol diet (HCD). In addition, the LA and FVF groups exhibited a significant increase in enzyme activity from multiple hepatic antioxidant systems including: superoxide dismutase, catalase, and gluthatione reductase/peroxidase as well as a decrease in MDA concentrations compared to HCD group. These results demonstrate that "triguero" asparagus possesses bioactive constituents, especially dietary fiber and flavonoids, that improve the plasma lipid profile and prevent hepatic oxidative damage under conditions of hypercholesterolemia.


Assuntos
Antioxidantes/metabolismo , Asparagus , Hipercolesterolemia/tratamento farmacológico , Extratos Vegetais/administração & dosagem , Animais , Catalase/sangue , Colesterol na Dieta/sangue , Fibras na Dieta/administração & dosagem , Flavonoides/administração & dosagem , Flavonoides/química , Hipercolesterolemia/metabolismo , Hipercolesterolemia/patologia , Lipídeos/sangue , Fígado/efeitos dos fármacos , Fígado/metabolismo , Masculino , Extratos Vegetais/química , Ratos , Saponinas/administração & dosagem , Saponinas/química , Superóxido Dismutase/sangue
3.
Clin Med (Lond) ; 18(1): 54-61, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-29436440

RESUMO

Alzheimer's disease (AD) is the most common type of dementia. Recent studies have assessed the possibility of using statins as treatment for AD. However, their efficacy is not clear. In this study, we collected the most relevant information about the efficacy of statins for the treatment of AD. We conducted a systematic literature search using MEDLINE, EMBASE and The Cochrane Library. We included clinical trials, meta-analyses and systematic reviews that analysed the efficacy of statins in AD. We also extracted the characteristics and efficacy results of the studies selected. Of the 304 articles identified, 13 complied with the inclusion criteria. The scientific quality of studies was high and their results indicated that there were no significant differences in the main efficacy variables between statins and placebo treatment for AD. Therefore, according to the available scientific evidence, statins have not shown an improvement in cognition and do not appear to offer significant benefits to patients with AD.


Assuntos
Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/psicologia , Cognição/efeitos dos fármacos , Humanos , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA